Publications
Hereditary Colorectal Cancer Syndromes.
Mork ME, You YN, Ying J, Bannon SA, Lynch PM, Rodriguez-Bigas MA, Vilar E. High Prevalence of Hereditary Cancer Syndromes in Adolescents and Young Adults With Colorectal Cancer. J Clin Oncol 33(31):3544-9, 11/2015. e-Pub 7/2015. PMCID: PMC4679241. (IF: 20.982, citations: 81)
de Rosa N, Rodriguez-Bigas MA, Chang GJ, Veerapong J, Borras E, Krishnan S, Bednarski B, Messick CA, Skibber JM, Feig BW, Lynch PM, Vilar E, You YN. DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. J Clin Oncol 34(25):3039-46, 9/2016. e-Pub 7/2016. PMCID: PMC5012714. (IF: 24.008, citations: 25)
Genomic Landscape of Premalignancy.
Borras E, San Lucas FA, Chang K, Zhou R, Masand G, Fowler J, Mork ME, You YN, Taggart MW, McAllister F, Jones DA, Davies GE, Edelmann W, Ehli EA, Lynch PM, Hawk ET, Capella G, Scheet P*, Vilar E*. Genomic Landscape of Colorectal Mucosa and Adenomas. Cancer Prev Res (Phila) 9(6):417-27, 6/2016. e-Pub 5/2016. PMCID: PMC4941624. (IF: 3.985, citations: 47)
Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome. JAMA Oncol 4(8):1085-1092, 8/2018. e-Pub 4/2018. PMCID: PMC6087485. (IF: 16.559, citations: 6)
San Lucas FA, Fowler J, Chang K, Kopetz S, Vilar E*, Scheet P*. Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes. Mol Cancer Ther. 2014 Dec;13(12):3230-40. PMCID: PMC4341901. (IF: 5.683, citations: 7)
Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Thirumurthi S, Kanth P, Delker DA, Hagedorn CH, Lynch PM, Ellis LM, Hawk ET, Scheet PA, Kopetz S, Arts J, Guinney J, Dienstmann R, Vilar E. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2. Ann Oncol 29(10):2061-2067, 10/2018. PMID: 30412224.(IF: 13.962, citations: 2)
Development of organoids as an in vitro platform for carcinogenesis and drug development studies.
Crespo M, Vilar E, Tsai SY, Chang K, Amin S, Srinivasan T, Zhang T, Pipalia NH, Chen HJ, Witherspoon M, Gordillo M, Xiang JZ, Maxfield FR, Lipkin S, Evans T, Chen S. Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nat Med. e-Pub 6/2017. PMID: 28628110. (IF: 29.886, citations: 67)
Lo YH, Noah TK, Chen MS, Zou W, Borras E, Vilar E, Shroyer NF*. SPDEF Induces Quiescence of Colorectal Cancer Cells by Changing the Transcriptional Targets of β-catenin. Gastroenterology. e-Pub 4/2017. PMID: 28390865. (IF: 18.392, citations: 8)
Molecular Biology of Mismatch Repair deficiency and its association to clinicopathological profiles, prognosis and sensitivity to chemotherapeutic agents.
Vilar E, Scaltriti M, Balmaña J, Saura C, Guzman M, Arribas J, Baselga J, Tabernero J. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br J Cancer. 2008 Nov 18;99(10):1607-12. PMCID: PMC2584960. (IF: 4.846, citations: 162)
Vilar E, Mukherjee B, Kuick R, Raskin L, Misek DE, Taylor JM, Giordano TJ, Hanash SM, Fearon ER, Rennert G, Gruber SB. Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res. 2009 Apr 15;15(8):2829-39. PMCID: PMC3425357. (IF: 6.747, citations: 62)
Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, Mukherjee B, Iniesta MD, Morgan MA, Rennert G, Gruber SB. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res. 2011 Apr 1;71(7):2632-42. PMCID: PMC3407272. (IF: 7.856, citations: 118)
Vilar E, Gruber SB. Microsatellite instability in colorectal cancer-the stable evidence. Nat Rev Clin Oncol 7(3):153-62, 2010, 3/2010. e-Pub 2/2010. PMCID: PMC3427139. (IF: 10.787, citations: 551)
Implementation of a clinical drug development program in hereditary cancer syndromes.
Reyes L, Lin R, Stoffel EM, Samadder NJ, Lynch P, Kanth P, Milne GL, Marnett LJ, Sepeda V, Liu D, You YN, Vornik LA, Lee J, Richmond E, Umar A, Perloff M, Lipkin SM, Brown PH, Vilar E. A phase Ib biomarker trial of naproxen in patients at risk for DNA mismatch repair deficient colorectal cancer. AACR Annual Meeting, 6/2018. (Abstract – CT065).
NCT02052908; https://clinicaltrials.gov/ct2/show/NCT02052908